Thymectomy for non-thymoma myasthenia gravis (MG)

Evidence-based neurology checklist on thymectomy for non-thymoma myasthenia gravis (mg): Indications Age < 45 years Generalised MG Within 2 years of disease onset Antibody positive No response to Pyridostigmine within 1 year of onset Benefits

Indications

  • Age < 45 years
  • Generalised MG
  • Within 2 years of disease onset
  • Antibody positive
  • No response to Pyridostigmine within 1 year of onset

Benefits

References

  1. Skeie GO, Apostolski S, Evoli A, et al. Guidelines for treatment of autoimmune neuromuscular transmission disorders. Eur J Neurol 2010; 17:893-902.
  2. Hilton-Jones D, Palace J. The management of myasthenia gravis. Pract Neurol 2005; 5:18-27.
  3. Gronseth GS, Barohn RJ. Practice parameter: thymectomy for autoimmune myasthenia gravis (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2000; 55:7–15.
  4. Gronseth GS, Barohn R, Narayanaswami P. Practice advisory: Thymectomy for myasthenia gravis (practice parameter update): Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology. Neurology 2020; 94:705-709. 
  5. Sanders DB, Wolfe GI, Benatar M, et al. International consensus guidance for management of myasthenia gravis: executive summary. Neurology 2016; 87:419-425.
  6. And 3 more. Subscribe to see the full list

Related checklists

Loading...